Core Viewpoint - Insurance capital is increasingly participating in cornerstone investments in Hong Kong IPOs, signaling strong market confidence, with significant investments from major insurance companies like Taikang Life and Ping An Life [1][3][4]. Group 1: Investment Trends - In early 2026, four insurance companies participated in eight Hong Kong IPO cornerstone investments, with Taikang Life investing $10 million in the IPO of Mingming Hen Mang [1]. - From 2025 to early 2026, seven insurance institutions participated as cornerstone investors in 20 Hong Kong IPOs, with a total subscription amount of HKD 4.679 billion [1][4]. - The average return for Hong Kong IPOs in 2025 was 38%, with the first-day price drop rate at a five-year low of 23.08% [6][10]. Group 2: Challenges Faced - Insurance companies face challenges in accessing IPO projects due to high entry barriers and the need for strong cross-market research capabilities [2][15]. - The balance between high return potential and net asset value volatility is a significant concern for insurance funds, which are generally risk-averse [2][15]. Group 3: Market Outlook - The IPO fundraising scale in Hong Kong is expected to remain strong in 2026, with insurance capital becoming a long-term force in the market [2][15][16]. - The cornerstone investment mechanism is seen as a key entry point for quality assets in the Hong Kong market, enhancing liquidity and valuation flexibility [2][16]. Group 4: Sector Focus - Insurance capital is focusing on sectors such as AI, biomedicine, and new consumer brands, with a notable interest in companies like MINIMAX and Ruibo Biotechnology [9][10]. - The investment strategy is shifting towards a more diversified valuation framework, moving beyond traditional profit metrics to include growth potential [10][11].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Beijing XSKY Technology Co., Ltd. 北京星辰天合科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、獨家保薦人、獨家保薦人兼整體協調人、整體協調人、 顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長 註冊的本公司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件 ...

Core Insights - The Hong Kong IPO market continues its strong momentum from the previous year, with over 350 companies currently waiting to list as of early 2026 [1][3] - In the first three weeks of the new year, Hong Kong has completed 11 IPOs, raising approximately $4 billion [1] Group 1: IPO Market Dynamics - As of early 2026, the number of companies waiting to list has increased from 316 at the end of 2025 to over 350 within a few weeks [3] - The surge in IPO applications is ongoing, with 16 companies submitting applications to the Hong Kong Stock Exchange in the first seven working days of January 2026 [3] - The IPO pipeline includes leading companies from various sectors, including technology and traditional industries, with notable names such as Ruipai Pet Medical and Anker Innovations [5] Group 2: Geographic and Sectoral Trends - Companies from both first-tier and lower-tier cities in China are actively pursuing listings in Hong Kong, with three companies from Henan province advancing their IPO plans within a week [5] - The IPO market is characterized by a concentration of leading firms across emerging and traditional sectors, with over 70% of listed companies in 2025 coming from information technology, biomedicine, new energy, and high-end manufacturing [12] Group 3: Historical Performance and Future Projections - In 2025, Hong Kong regained its position as the top global IPO market, with 119 IPOs and a total fundraising amount of 2858 billion HKD, marking a 68% increase from 2024 [14] - Predictions for 2026 suggest that the IPO fundraising scale could exceed 300 billion HKD, with estimates ranging from 320 billion to 350 billion HKD and around 150 to 180 companies expected to successfully list [14][12] Group 4: Quality and Market Sentiment - The Hong Kong Stock Exchange emphasizes the importance of IPO quality, acknowledging that the recent surge in applications has led to some lower-quality submissions [16] - There is a growing trend of differentiation in the market, where larger projects and industry leaders are more likely to attract long-term funding, while smaller projects may face challenges based on market conditions and performance [16]

Group 1 - The Hong Kong stock market witnessed a competitive IPO environment at year-end, with six companies debuting and five opening higher, collectively expected to raise nearly 6 billion HKD [1] - AI pharmaceutical platform InSilico Medicine led the gains, opening at 35 HKD, a 45.5% increase from the offering price of 24.05 HKD, with a potential profit of 5,475 HKD per lot [1] - High-end cosmetics company Lin Qingxuan opened at 85 HKD, up 9.3% from the offering price of 77.77 HKD, yielding a profit of 361.5 HKD per lot [1] Group 2 - The performance of household robotics developer Woan Robotics was relatively weak, opening at 73.8 HKD, unchanged from the offering price [1] - Real-time data infrastructure and analytics solutions provider XunCe opened at 48.02 HKD, a slight increase of 0.1% from the offering price of 48 HKD, with a profit of 2 HKD per lot [1] - Prefabricated steel structure construction service company Meilian Holdings opened at 8.21 HKD, a 15.6% increase from the offering price of 7.1 HKD, resulting in a profit of 333 HKD per lot [1] Group 3 - The IPO event marked the second occurrence of "six bells ringing" at the Hong Kong Stock Exchange this year, with the previous instance on July 9 [1] - Digital twin technology company Wuyi Shijie opened at 35 HKD, a 14.8% increase from the offering price of 30.5 HKD, with a profit of 900 HKD per lot [1]

Global IPO Market Overview - The global IPO fundraising amount for 2025 is projected to reach $158.4 billion, an increase of 18% compared to 2024 [1] - Hong Kong is expected to lead the global IPO market with $34.3 billion, surpassing the New York Stock Exchange and NASDAQ [1][10] - Key drivers for this growth include the return of Chinese concept stocks, the A+H listing system, and increased foreign investment participation [1][3] Hong Kong IPO Market - Hong Kong's IPO market is set to benefit significantly from the return of Chinese companies, with three companies expected to list in 2025 compared to none in 2024 [1] - The A+H listings have seen a record number of applications, with 109 applications processed, and the average listing time reduced to 4-6 months [1][29] - Major IPOs in Hong Kong include Ningde Times with HKD 41 billion and 恒瑞医药 with HKD 11.4 billion [28] A-share Market Overview - The A-share IPO market is projected to have 130 IPOs raising approximately RMB 130 billion, a decrease of 28% from the previous year [2] - The market is characterized by a contraction in the main board and expansion in the Sci-Tech Innovation Board and Beijing Stock Exchange [2] - The introduction of REITs has stabilized the market, with 20 listings, while traditional manufacturing sectors have seen a decline in fundraising [2][13] 2026 Outlook - The Hong Kong market is expected to continue its growth driven by A+H listings, special technology sectors, and increased participation from Middle Eastern and Southeast Asian sovereign funds [3][10] - The A-share market is anticipated to implement reforms allowing unprofitable companies to list with options, aiming to counteract the pressure from Hong Kong [2][3] - Potential risks include fluctuating U.S. Federal Reserve policies and geopolitical tensions affecting foreign investment [3]

Core Insights - The Hong Kong IPO market has shown a strong recovery, with the listing of JD Industrial marking the 100th new stock in 2025, highlighting the market's resilience and attractiveness as an international financial center [1] Group 1: IPO Market Performance - In 2025, the Hong Kong IPO market raised over 270 billion HKD, significantly surpassing the previous year's figures and marking the second highest fundraising level in five years [2] - The Hong Kong Stock Exchange (HKEX) is projected to lead globally in fundraising with approximately 36 billion USD (about 280.8 billion HKD) in 2025, outpacing the New York Stock Exchange's expected 20.5 billion USD [2] - Eight new stocks raised over 10 billion HKD each, with CATL leading at 41.006 billion HKD, setting a record for the largest IPO globally this year [2] Group 2: Large IPOs and Sector Contributions - Large IPOs have been a key driver of the Hong Kong market's resurgence, with over 20 A-share companies expected to debut in Hong Kong, raising over 170 billion HKD collectively [3] - The average fundraising size has increased by 137% compared to last year, reaching the second highest level in five years, with industrial and retail sectors dominating [3] Group 3: Technology Sector Dominance - Technology-related companies have emerged as the main force in the IPO wave, particularly those under Chapter 18A (unprofitable biotech companies) and Chapter 18C (specialized technology companies) [3] - In 2025, 14 companies listed under Chapter 18A, a 250% increase from 2024, focusing on innovative fields such as cancer treatment and gene editing [4] Group 4: Market Outlook and Predictions - Major institutions are optimistic about the 2026 IPO market, predicting 150 to 200 new listings and fundraising exceeding 300 billion HKD [6] - UBS forecasts that the Hong Kong market will maintain its position as the top fundraising venue, with several large IPOs expected in January [6] Group 5: Recommendations for Companies - Companies planning to go public are advised to embrace technology and build integrated financial governance systems to ensure data transparency and compliance with regulatory standards [7]

Core Viewpoint - Chengdu Kanopu Robot Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to go public through the 18C special technology channel on the main board [1][3] Financial Performance - In 2024, Kanopu's revenue is projected to be 234 million yuan, approximately 258 million HKD, just meeting the 250 million HKD listing threshold for commercialized companies [2][5] - The company's R&D expenditure is 36 million yuan, accounting for 15.4% of its revenue, closely aligning with the requirement of at least 15% for listing [2][6] - R&D spending has been declining year-on-year, with core patents mostly obtained over ten years ago [2][7] - Kanopu's operating cash flow has been negative for two consecutive years, and accounts payable has significantly increased, indicating urgent need for listing [11][21] Market Position - Kanopu is the largest welding robot manufacturer in China and ranks first among Chinese manufacturers in key welding robot segments, including laser welding and cutting robots [19] - Despite its leading position in terms of gross margin, Kanopu's revenue scale remains small compared to comparable companies like Estun and Efort [19][21] - The company achieved a net profit of 8 million yuan in the first half of the year, becoming one of the few in the industry to turn a profit [21] Dependency on Subsidies - Government subsidies have significantly contributed to Kanopu's revenue, with amounts of 40.1 million, 20.8 million, and 10.3 million yuan recorded from 2022 to 2024, and 5.7 million yuan in the first half of the current year, making up 67% of the net profit [11][21] - The proportion of overseas revenue has been declining, from 15.6% in 2022 to 9.1% in the first half of 2023, which may pressure future performance [11][21] Listing Strategy - The 18C special technology company listing rules allow companies to go public without profitability, significantly easing the requirements for profitability and market capitalization [4][14] - For commercialized companies, the market capitalization must be no less than 4 billion HKD, and R&D expenditure must be at least 15% of operating expenses over the last three years [5][15]

Core Viewpoint - Shanghai XianGong Intelligent Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the second time this year, with CICC as its sole sponsor [1]. Group 1: Company Overview - XianGong Intelligent is an intelligent robotics company focused on robot control systems, integrating supply chain resources to provide comprehensive robot solutions for real-world applications [1][4]. - The company aims to eliminate barriers to the development, acquisition, and use of intelligent robots by offering a one-stop solution that includes controllers, software, robots, and accessories [4]. Group 2: Market Position - The company leverages its market position and leading technology in robot control systems, referred to as the "robot brain," to enhance its offerings [1].

Group 1 - The core point of the article is that Shanghai XianGong Intelligent Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the second time this year, with China International Capital Corporation as its sole sponsor [1] - The company previously submitted its listing application on May 27 [1] - XianGong Intelligent focuses on robot control systems and aims to provide a one-stop robotic solution for development, acquisition, and usage in real-world scenarios [1][4] Group 2 - XianGong Intelligent offers a comprehensive solution that includes controllers, software, robots, and accessories, aiming to eliminate barriers to the development, acquisition, and use of intelligent robots [4] - All of the company's products are defined as specialized technology products under Chapter 18C of the listing rules [4]

Core Insights - The Hong Kong IPO market has seen a significant presence of biopharmaceutical companies, with most listing under the HKEX Chapter 18A for unprofitable biotech firms, achieving strong first-day performance with many stocks rising over 100% [1] - The geographical distribution of these listings is concentrated, with 13 out of 19 biopharmaceutical companies coming from the Yangtze River Delta region, which includes 7 from Jiangsu, 4 from Zhejiang, and 2 from Shanghai [1] - The Yangtze River Delta contributes 30% of the national biopharmaceutical output, 30% of drug sales, and 70% of domestically produced Class 1 new drugs, with an industry value exceeding 1 trillion [1] - Additionally, 6 companies have listed under HKEX Chapter 18C for specialized technology firms, with 3 of these from the Guangzhou-Shenzhen area [1] - Market analysis suggests that as new first-tier cities enhance their IPO cultivation efforts, combined with the Hong Kong market's inclination towards specialized technology sectors, future mainland IPOs are expected to exhibit a "core leading, multi-point blossoming" trend [1] - Local governments are encouraged to align their local industry characteristics with the demands of the Hong Kong stock market [1]